Adenocarcinoma of the Uterus

Clinical Gynecologic Oncology

Volumn , Issue , 2007, Pages 147-184

  Creasman, William T ^a  

^a MEDICAL UNIVERSITY OF SOUTH CAROLINA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 52049106249     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.1016/B978-032303978-9.50008-3     Document Type: Chapter

References (283)

1. Antunes CMF, Strolley PD, Rosenshein NB, et al. Endometrial cancer and estrogen use (report of a large case-control study). N Engl J Med 1979, 300:9.
2. Barakat RR The effects of tamoxifen on the endometrium. Oncology (Huntingt) 1995, 9:129.
3. Barakat RR, Eonf G, Curain JP Tamoxifen use in breast cancer patients who subsequently develop corpus cancer is not associated with a higher incidence of adverse histological features. Gynecol Oncol 1994, 55:164.
4. Beresford SA, Weiss NS, Voigt LF, McKnight B. Risk of endometrial cancer in relation to use of oestrogen combined with cyclic progestogen therapy in postmenopausal women. Lancet 1997, 349:458.
5. Brinton LA, Berman ML, Mortel R, et al. Reproductive, menstrual, and medical risk factors for endometrial cancer: Results from a case-control study. J Obstet Gynecol 1992, 167:1317.
6. Oral contraceptive use and the risk of endometrial cancer. JAMA 1983, 249:1600. Centers for Disease Control Cancer and Steroid Hormone Study.
7. Evans-Metcalf ER, Brooks SE, Reale FR, Baker SP Profiles of women 45 years of age and younger with endometrial cancer. Obstet Gynecol 1998, 91:349.
8. Fisher B, Costantino JP, Wickerham DL, et al. Tamoxifen for prevention of breast cancer: Report of the National Surgical Adjuvant Breast and Bowel Project P-1 study. J Natl Cancer Inst 1998, 90:1371.
9. Gray LA, Christopherson WM, Hoover RN Estrogens and endometrial carcinoma. Obstet Gynecol 1977, 49:385.
10. Greenblatt RB, Stoddard LB The estrogen-cancer controversy. J Am Geriatr Soc 1978, 26:1.
11. Gusberg SB, Kardon P. Proliferative endometrial response to thecal granulosa cell tumors. Am J Obstet Gynecol 1971, 3:633.
12. Hoffman K, Nekhylndov L, Deligdisch L. Endometrial carcinoma in elderly women. Gynecol Oncol 1995, 58:198.
13. Hoover R, Fraumeni JF, Everson R, et al. Cancer of the uterine corpus after hormonal treatment for breast cancer. Lancet 1976, 1:885.
14. Horwitz RL, Feinstein AF Alternative analytic methods for case-control studies of estrogens and endometrial cancer. N Engl J Med 1978, 299:1090.
15. Husslein H, Brietenecker G, Tatra G. Premalignant and malignant uterine changes in immunosuppressed renal transplant recipients. Acta Obstet Gynecol Scand 1978, 57:73.
16. Jordan VC, Assikis VJ Endometrial carcinoma and tamoxifen: Clearing up a controversy. Clin Cancer Res 1995, 1:467.
17. Kaku T, Matsumura M, Sakai K, et al. Endometrial carcinoma in women 65 years of age or older: A clinicopathologic study. Eur J Gynaecol 1996, 17:357.
18. Kaplan DS, Cole P: Epidemiology of cancer of the endometrium (in press).
19. Kelley HW, et al. Adenocarcinoma of the endometrium in women taking sequential oral contraceptives. Obstet Gynecol 1972, 47:200.
20. Killackey MA, Hakes TB, Pierce VK Endometrial adenocarcinoma in breast cancer patients receiving antiestrogens. Cancer Treat Rep 1985, 69:273.
21. Lawrence C, et al. Smoking, body weight, and early stage endometrial cancer. Cancer 1987, 59:1665.
22. Levi F, Franeschi S, Negri E, LaVecchia C. Dietary factors and the risk of endometrial cancer. Cancer 1993, 71:3775.
23. MacMahon B Risk factors for endometrial cancer. Gynecol Oncol 1974, 2:122.
24. MacMahon B Overview of studies on endometrial cancer and other types of cancer in humans: Perspective of an epidemiologist. Semin Oncol 1997, 24:S1.
25. Mack TM, et al. Estrogens and endometrial cancer in a retirement community. N Engl J Med 1976, 294:1262.
26. Mansell H, Hertig AT Granulosa-theca cell tumor and endometrial carcinoma: A study of their relationship and survey of 80 cases. Obstet Gynecol 1955, 6:385.
27. McCarty KS, et al. Gonadal dysgenesis with adenocarcinoma of the endometrium: Electron microscopic and steroid receptor analyses with a review of the literature. Cancer 1978, 42:510.
28. McDonald TW, Malkasian GD, Gaffey TA Endometrial cancer associated with feminizing ovarian tumors and polycystic ovarian disease. Obstet Gynecol 1977, 94:654.
29. Endometrial cancer and hormone replacement therapy in the Million Women Study. Lancet 2005, 365:1543. Million Women Study Collaborators.
30. Novak E, Yui E. Relationship of endometrial hyperplasia to adenocarcinoma of the endometrium. Am J Obstet Gynecol 1936, 32:674.
31. Nyholm NCV, Neilsen AL, Norup P. Endometrial cancer in postmenopausal women with and without previous estrogen replacement treatment: Comparison of clinical and histopathological characteristics. Gynecol Oncol 1993, 49:229.
32. Ostor AG, et al. Endometrial carcinoma in gonadal dysgenesis with and without estrogen therapy. Gynecol Oncol 1978, 6:316.
33. Pacheco JC, Kempers RD Etiology of post-menopausal bleeding. Obstet Gynecol 1968, 32:40.
34. Powels T, Eeles R, Ashley S, et al. Interim analysis of the incidence of breast cancer in the Royal Marsden Hospital tamoxifen randomised chemoprevention trial. Lancet 1998, 352:98.
35. Schapira DV, Kumar NB, Lyman GH, et al. Upper-body fat distribution and endometrial cancer risk. JAMA 1991, 266:1808.
36. Silva EG, Tornos C, Mapica A, Mitchell MF Uterine neoplasms in patients treated with tamoxifen. J Cell Biochem Suppl 1995, 23:179.
37. Silverberg SG, Makowski EL Endometrial carcinoma in young women taking oral contraceptives agents. Obstet Gynecol 1975, 46:503.
38. Smith DC, et al. Association of exogenous estrogen and endometrial carcinoma. N Engl J Med 1975, 293:1164.
39. Swanson CA, Potischman N, Wilbanks GD, et al. Relationship of endometrial cancer risk to past and contemporary body size and body fat distribution. Cancer Epidemiol Biomarkers Prev 1993, 2:321.
40. Veronesi U, Maisonneuve P, Costa A, et al. Prevention of breast cancer with tamoxifen: Preliminary findings from the Italian randomised trial among hysterectomised women. Lancet 1998, 352:93.
41. Weiderpass E, Adami HO, Baron JA, et al. Risk of Endometrial Cancer Following Estrogen Replacement With and Without Progestins. J Natl Cancer Inst 1999, 91:1131-1137.
42. Weiss NS Non-contraceptive estrogens and abnormalities of endometrial proliferation. Ann Intern Med 1978, 88:410.
43. Ziel HK, Finkle WD Increased risk of endometrial carcinoma among users of conjugated estrogens. N Engl J Med 1975, 293:1167.
44. Ziel HK, Finkle WD, Greenland S. Decline in incidence of endometrial cancer following increase in prescriptions for opposed conjugated estrogens in a prepaid health plan. Gynecol Oncol 1998, 68:253.
45. Abate SD, Edwards CL, Vellias F. A comparative study of the endometrial jet-washing technique and endometrial biopsy. Am J Clin Pathol 1972, 58:118.
46. Anderson B Diagnosis of endometrial cancer. Clin Obstet Gynecol 1986, 13:739.
47. Assikis VJ, Jordan VC A realistic assessment of the association between tamoxifen and endometrial cancer. Endocr Rel Cancer 1995, 2:1.
48. Berezowsky J, Chalvardjian A, Murray D. Iatrogenic endometrial mega polyps in women with breast carcinoma. Obstet Gynecol 1994, 84:727.
49. Bourne TH, Campbell S, Steer CV, et al. Detection of endometrial cancer by transvaginal ultrasonography with color flow imaging and blood flow analysis. Gynecol Oncol 1991, 40:253.
50. Cacciatore B, Lehtovirta P, Wahlstrom T, et al. Preoperative sonographic evaluation of endometrial cancer. Am J Obstet Gynecol 1989, 160:133.
51. Cohen CJ, Gusberg SB Screening for endometrial cancer. Clin Obstet Gynecol 1975, 18:27.
52. Cohen I, Rosen DJD, Shapira J, et al. Endometrial changes with tamoxifen: Comparison between tamoxifen-treated and nontreated asymptomatic postmenopausal breast cancer patients. Gynecol Oncol 1994, 52:185.
53. Creasman WT Endometrial cancer: Incidence, prognostic factors, diagnosis, and treatment. Semin Oncol 1997, 24:S1.
54. Creasman WT, Weed JC Screening techniques in endometrial cancer. Cancer 1976, 38:436.
55. Doering DL, Barnhill DR, Weiser EB, et al. Intraoperative evaluation of depth of myometrial invasion in stage I endometrial carcinoma. Obstet Gynecol 1989, 74:930.
56. Feldman S, Cook EF, Harlow BL, Berkowitz RS Predicting endometrial cancer among older women who present with abnormal vaginal bleeding. Gynecol Oncol 1995, 56:376.
57. Fisher B, Costantino JP, Redmond CK, et al. Endometrial cancer in tamoxifen treated breast cancer patients: Findings from the National Surgical Adjuvant Breast and Bowel Project (NSABP) B-14. J Natl Cancer Inst 1994, 86:527.
58. Giusa-Chiferi MG, Goncalves WJ, Baracat EC, et al. Transvaginal ultrasound, uterine biopsy and hysteroscopy for postmenopausal bleeding. Int J Gynaecol Obstet 1996, 55:39.
59. Goldchmit R, Katz Z, Blickstein I, et al. The accuracy of endometrial Pipelle sampling with or without sonographic measurement of endometrial thickness. Obstet Gynecol 1993, 82:727.
60. Goldstein SR Unusual ultrasound appearance of the uterus in patients receiving tamoxifen. Am J Obstet Gynecol 1994, 170:447.
61. Gordon AN, Fleischer AC, Dudley BS, et al. Preoperative assessment of myometrial invasion of endometrial adenocarcinoma by ultrasound and MRI. Gynecol Oncol 1989, 34:175.
62. Granberg S, Wikland M, Karlson B, et al. Endometrial thickness as measured by endovaginal ultrasound for identifying endometrial abnormality. Am J Obstet Gynecol 1991, 164:47.
63. Gupta JK, Wilson S, Desai P, Hau C How should we investigate women with postmenopausal bleeding?. Acta Obstet Gynecol Scand 1996, 75:475.
64. Hofmeister FJ Endometrial biopsy: Another look. Am J Obstet Gynecol 1974, 118:733.
65. Horwitz RJ, Horwitz SM, Feinstein AR, et al. Necropsy diagnosis of endometrial cancer and detection bias in case/control studies. Lancet 1981, 2:66.
66. Ismail SM Pathology of endometrium treated with tamoxifen. J Clin Pathol 1994, 47:827.
67. Kedar RP, Bourne TH, Powles TJ, et al. Effects of tamoxifen on uterus and ovaries of postmenopausal women in a randomized breast cancer prevention trial. Lancet 1994, 343:1318.
68. Koss LG, Schreiber K, Oberlander SG, et al. Detection of endometrial carcinoma in hyperplasia in asymptomatic women. Obstet Gynecol 1984, 64:1.
69. Lahti E, Blanco G, Kauppila A, et al. Endometrial changes in postmenopausal breast cancer patients receiving tamoxifen. Obstet Gynecol 1993, 81:660.
70. Langer RD, Pierce JJ, O'Hanlan KA, et al. Transvaginal ultrasonography compared with endometrial biopsy for the detection of endometrial disease. N Engl J Med 1997, 337:1792.
71. Lu KH, Dinh M, Kohlmann W, et al. Gynecologic Cancer as a "Sentinel Cancer" for Women With Hereditary Nonpolyposis Colorectal Cancer Syndrome. Obstet Gynecol 2005, 105:569.
72. Magriples U, Naftolin F, Schwartz PE, et al. High grade endometrial carcinoma in tamoxifen treated breast cancer patients. J Clin Oncol 1993, 11:485.
73. Maia H, Barbosa IC, Farias JP, et al. Evaluation of the endometrial cavity during menopause. Int J Gynecol Obstet 1996, 52.
74. Nasri MH, Coast CJ Correlation of ultrasound findings and endometrial histopathology in postmenopausal women. Br J Obstet Gynaecol 1989, 96:1333.
75. Reich O, Winter R, Pickel H, et al. Does the size of pelvic lymph nodes predict metastatic involvement in patients with endometrial cancer?. Int J Gynecol Cancer 1996, 6:445.
76. Smith-Bindman R, Kerlikowske K, Feldstein VA, et al. Endovaginal ultrasound to exclude endometrial cancer and other endometrial abnormalities. JAMA 1998, 280:1510.
77. Stovall TG, Photopulos GJ, Poston WM, et al. Pipelle endometrial sampling in patients with known endometrial carcinoma. Obstet Gynecol 1991, 77:954.
78. Varner RE, Sparks JM, Cameron CD, et al. Transvaginal sonography of the endometrium in postmenopausal women. Obstet Gynecol 1991, 78:195.
79. Vuento MH, Maatela JI, Tyrkko JE, et al. A longitudinal study of screening for endometrial cancer by endometrial biopsy in diabetic females. Int J Gynecol Cancer 1995, 5:390.
80. Weber AM, Belinsob JL, Bradley LD, Piedmonte MR Vaginal ultrasonography versus endometrial biopsy in women with postmenopausal bleeding. Am J Obstet Gynecol 1997, 177:924.
81. Ambros RA, Kurman RJ Identification of patients with stage I uterine endometrial adenocarcinoma at high risk of recurrence by DNA ploidy myometrial invasion and vascular invasion. Gynecol Oncol 1992, 45:235.
82. Ayhan A, Turner R, Turner ZS, et al. Correlation between clinical and histopathologic risk factors; i.e., lymph node metastasis in early endometrial cancer. Int J Obstet Gynecol 1994, 4:306.
83. Baak JPA, Snijders WP, Van Diest PJ, et al. Confirmation of the prognostic value of the ECPI-1 score in FIGO stage I endometrial cancer patients with long follow up. Int J Gynecol Cancer 1995, 5:112.
84. Benraad TJ, et al. Do estrogen and progesterone receptors (E2R and PR) in metastasizing endometrial cancer predict the response to gestagen therapy?. Acta Obstet Gynecol Scand 1980, 59:155.
85. Bokhman JV Two pathogenetic types of endometrial carcinoma. Gynecol Oncol 1983, 15:10.
86. Boronow RC, et al. Surgical staging in endometrial cancer: Clinical-pathologic findings of a prospective study. Obstet Gynecol 1984, 63:825.
87. Bristow RE, Zahurak ML, Alexander CJ, et al. FIGO stage IIIC endometrial carcinoma: Resection of macroscopic nodal disease and other determinants of survival. Int J Gynecol Cancer 2003, 13:664.
88. Britton LC, Wilson TO, Gaffey TA, et al. DNA ploidy in endometrial carcinoma: Major objective prognostic factor. Mayo Clin Proc 1990, 65:643.
89. Connell PP, Rotmensch J, Waggoner S, Mundt AJ Significance of adnexal involvement in endometrial carcinoma. Gynecol Oncol 1999, 74:74.
90. Cowles TA, et al. Comparison of clinical and surgical staging in patients with endometrial cancer. Obstet Gynecol 1985, 66:413.
91. Creasman WT, Rutledge FN The prognostic value of peritoneal cytology in gynecologic malignant disease. Am J Obstet Gynecol 1971, 110:773.
92. Creasman WT, DiSaia PJ, Blessing J. Prognostic significance of peritoneal cytology in patients with endometrial cancer and preliminary data concerning therapy with intraperitoneal radiopharmaceuticals. Am J Obstet Gynecol 1981, 141:921.
93. Creasman WT, McCarty KS, McCarty KS Clinical correlation of estrogen, progesterone binding proteins in human endometrial adenocarcinoma. Obstet Gynecol 1980, 55:363.
94. Creasman WT, Morrow CP, Bundy L. Surgical pathological spread patterns of endometrial cancer. Cancer 1987, 60:2035.
95. Creasman WT, et al. Adenocarcinoma of the endometrium: Its metastatic lymph node potential. A preliminary report. Gynecol Oncol 1976, 4:239.
96. Creasman WT, et al. Influence of cytoplasmic steroid receptor content on prognosis of early stage endometrial carcinoma. Am J Obstet Gynecol 1985, 151:922.
97. Dasarahally S, Mohan MA, Samuels MA, et al. Long-Term Outcomes of Therapeutic Pelvic Lymphadenectomy for Stage I Endometrial Adenocarcinoma. Gynecol Oncol 1985, 70:165-171.
98. DiSaia PJ, et al. Risk factors in recurrent patterns in stage I endometrial carcinoma. Am J Obstet Gynecol 1998, 151:1009.
99. Ehrlich CE, Young PCM, Cleary RE Cytoplasmic progesterone and estriol receptors in normal, hyperplastic, and carcinomatous endometria: Therapeutic implications. Am J Obstet Gynecol 1981, 141:539.
100. Eltabbakh GH, Moore AD Survival of women with surgical stage II endometrial cancer. Gynecol Oncol 1999, 74:80.
101. Genest P, et al. Prognostic factors in early carcinoma of the endometrium. Am J Clin Oncol 1987, 10:71.
102. Goff BA, Kato D, Schmidt RA, et al. Uterine papillary serous carcinoma: Patterns of metastatic spread. Gynecol Oncol 1994, 54:264.
103. Grice J, Ek M, Greer B, et al. Uterine papillary serous carcinoma: Evaluation of long-term survival in surgically staged patients. Gynecol Oncol 1998, 69:69.
104. Grimshaw RN, Tupper WC, Fraser RC, et al. Prognostic value of peritoneal cytology in endometrial carcinoma. Gynecol Oncol 1990, 36:97.
105. Hanson NB, et al. Prognostic significance of lymph-vascular space invasion in stage I endometrial cancer. Cancer 1985, 55:1753.
106. Haroung VR, Sutton EP, Clark SA, et al. The importance of peritoneal cytology in endometrial carcinoma. Obstet Gynecol 1988, 72:394.
107. Havrilesky LJ, Crogum JM, Calingaert B, et al. resection of lymph node metastases influences survival in Stage III endometrial cancer. Gynecol Oncol 2005, 99:689-695.
108. Kauppila A Oestrogen and progestin receptors as prognostic indicators in endometrial cancer. Acta Oncol 1989, 28:561.
109. Kauppila A, Grönroos N, Nieminen U. Clinical outcome in endometrial cancer. Obstet Gynecol 1982, 60:473.
110. Kodama S, Kase H, Tanaka K, Matsui K. Multivariate analysis of prognostic factors in patients with endometrial cancer. Int J Gynecol Obstet 1996, 53:23.
111. Konski A, Poulter C, Keys H, et al. Absence of prognostic significance, peritoneal dissemination and treatment advantage in endometrial cancer patients with positive peritoneal cytology. Int J Radiat Oncol Biol Phys 1988, 4:49.
112. Lefevre H Node dissection in cancer of the endometrium. Surg Gynecol Obstet 1956, 102:649.
113. Levenback C, Burke TW, Silva E, et al. Uterine papillary serous carcinoma treated with PAC. Gynecol Oncol 1992, 46:317.
114. Lo SST, Cheng DKL, Ng TY, et al. The prognostic significance of positive peritoneal cytology in endometrial cancer. Int J Gynecol Cancer 1996, 6:473.
115. Lurian JR, Rum Sey NK, Schink JC, et al. Prognostic significance of positive peritoneal cytology in clinical stage I adenocarcinoma of the endometrium. Obstet Gynecol 1989, 74:175.
116. Lutz MH, et al. Endometrial carcinoma: A new method of classification of therapeutic and prognostic significance. Gynecol Oncol 1978, 6:83.
117. Mariani A, Webb MJ, Galli L, Podratz KC Potential Therapeutic Role of Para-aortic Lymphadenectomy in Node-Positive Endometrial Cancer. Gynecol Oncol 2000, 348.
118. Matsushima-Nishiu M, Unoki M, Ono K, et al. Growth and gene expression profile analyses of endometrial cancer cells expressing exogenous PTEN. Cancer Research 2001, 61:3741-3749.
119. Matthews RP, Hutchinson-Colas J, Maiman M, et al. Papillary serous and clear cell type lead to poor prognosis of endometrial carcinoma in black women. Gynecol Oncol 1997, 65:265.
120. Milosevic MF, Dembo AD, Thomas GM Clinical significance of malignant peritoneal cytology in stage I endometrial carcinoma. Int J Gynecol Cancer 1992, 2:225.
121. Morrow CP, Bundy BN, Kurman RJ, et al. Relationship between surgical pathological risk factors and outcome in clinical stage I and II carcinoma of the endometrium. Gynecol Oncol 1991, 40:55.
122. Nolan JF, Huen A. Prognosis in endometrial cancer. Gynecol Oncol 1976, 4:384.
123. Nordström B, Strang P, Lindgren A, et al. Endometrial carcinoma: The prognostic impact of papillary serous carcinoma (UPSC) in relation to nuclear grade, DNA ploidy and p53 expression. Anticancer Res 1996, 16:899.
124. Norris HJ, Taylor HG Prognosis of granulosa thecal tumor of the ovary. Cancer 1968, 21:255.
125. Onda T, Yeshikawa H, Mizutani K, et al. treatment of node positive endometrial cancer with complete node dissection, chemotherapy and radiation therapy. Br J Cancer 1997, 75:183.
126. Onsrud N, et al. Endometrial carcinoma with cervical involvement (stage II): Prognostic factors in value of combined radiological surgical treatment. Gynecol Oncol 1982, 13:76.
127. Pfisterer J, Kommoss F, Sauerbrei V, et al. Prognostic value of DNA ploidy and S-phase fraction in stage I endometrial carcinoma. Gynecol Oncol 1995, 58:149.
128. Pisani A, Barbuto DA, Chen D, et al. HER-2/neu, p53, and DNA analysis as prognosticators for survival in endometrial carcinoma. Obstet Gynecol 1995, 85:729.
129. Plentyl AA, Friedman EA Lymphatic System of the Female Genitalia: The Morphologic Basis of Oncologic Diagnosis and Therapy 1971, WB Saunders, Philadelphia.
130. Podratz KC, Wilson TO, Gaffey TA, et al. DNA analysis facilitates the pretreatment identification of high-risk endometrial cancer patients. Am J Obstet Gynecol 1993, 168:1206.
131. Podratz KC, Mariani A, Webb MJ Staging and Therapeutic Value of Lymphadenectomy in Endometrial Cancer. Gynecol Oncol 1998, 70:163-164.
132. Pollow K, Manz B, Grill JH Estrogen progesterone receptors in endometrial carcinoma. Steroids and Endometrial Cancer 1989, 101. Raven Press, New York. V.M. Jasonni (Ed.).
133. Potish RA, et al. Para-aortic lymph node radiotherapy in the cancer of uterine corpus. Obstet Gynecol 1985, 65:251.
134. Quinn MA, Couchi M, Fortune V. Endometrial carcinoma: Steroid receptors and response to medroxyprogesterone acetate. Gynecol Oncol 1985, 21:314.
135. Rosenberg P, Boeryd B, Simonsen E. A new aggressive treatment approach to high grade endometrial cancer of possible benefit to patients with stage I uterine papillary cancer. Gynecol Oncol 1993, 48:32.
136. Rutledge FN, Tan S, Fletcher G. Vaginal metastases from adenocarcinoma of the corpus uteri. Am J Obstet Gynecol 1958, 75:157.
137. Sandstrom RE, Welch WR, Green TH Adenocarcinoma of the endometrium in pregnancy. Obstet Gynecol 1979, 53(Suppl):735.
138. Schink JC, et al. Tumor size in endometrial cancer: A prospective factor for lymph node metastases. Obstet Gynecol 1987, 70:216.
139. Sherman ME, Sturgeon S, Brinton LA, et al. Risk factors and hormone levels in patients with serous and endometrioid uterine carcinomas. Mod Pathol 1997, 10:963.
140. Soper JT, et al. Intraperitoneal chromic phosphate P-32 suspension therapy in malignant peritoneal cytology and endometrial carcinoma. Am J Obstet Gynecol 1985, 153:191.
141. Sorbe B, Risberg B, Thonthwaite J. Nuclear morphometry and DNA flow cytometry as prognostic methods for endometrial carcinoma. Int J Gynecol Cancer 1994, 4:94.
142. Surwit EA, et al. Stage II carcinoma of the endometrium. Int J Radiat Oncol Biol Phys 1979, 5:323.
143. Susini T, Rapi S, Savino L, et al. Prognostic value of flow cytometric deoxyribonucleic acid in endometrial carcinoma: Comparison with other clinical-pathologic parameters. Am J Obstet Gynecol 1994, 170:527.
144. Sutton GP The significance of positive peritoneal cytology in endometrial cancer. Oncology 1990, 4:21.
145. Takeshima N, Hirai Y, Tanaka N, et al. Pelvic lymph node metastasis in endometrial cancer with no myometrial invasion. Obstet Gynecol 1996, 88:280.
146. Takeshima N, Hirai Y, Yano K, et al. Ovarian metastasis in endometrial carcinoma. Gynecol Oncol 1998, 70:183.
147. Thornton JE, Ali S, O'Donovan P, et al. Flow cytometric studies of ploidy and proliferative indices in the Yorkshire trial of adjuvant progestogen treatment of endometrial cancer. Br J Obstet Gynaecol 1993, 100:253.
148. Turner DA, Gershenson DM, Atkinson N, et al. The prognostic significance of peritoneal cytology for stage I endometrial cancer. Obstet Gynecol 1989, 74:775.
149. Van Nostrand K, Johnson G, Monk B, et al. Genetic alterations in endometrial carcinomas. Int J Gynecol Cancer 1998, 8:415.
150. Von Minckwitz G, Kuhn W, Kaufmann M, et al. Prognostic importance of DNA ploidy and S-phase fraction in endometrial cancer. Int J Gynecol Cancer 1994, 4:250.
151. Yazigi R, Piver MS, Blumenson L. Malignant peritoneal cytology as prognostic indicator in stage I endometrial cancer. Obstet Gynecol 1983, 62:359.
152. Abeler UA, Kjorstad KE Endometrial adenocarcinoma with squamous cell differentiation. Cancer 1992, 69:488.
153. Alberhasky RC, Connely PJ, Christopherson WN Carcinoma of the endometrium. IV: Mixed adenosquamous carcinoma. Am J Clin Pathol 1982, 77:655.
154. Aozasa K, Saeki K, Ohasawa M, et al. Malignant lymphoma of the uterus. Cancer 1993, 72:1959.
155. Benedetti-Panici P, Maneschi F, Cutillo G, et al. Anatomical and pathological study of retroperitoneal nodes in endometrial cancer. Int J Gynecol Cancer 1998, 8:322.
156. Chambers JT, Merino M, Kohorn EI, et al. Uterine papillary serous carcinoma. Obstet Gynecol 1987, 69:109.
157. Chen JL, Trost DC, Wilkinson EJ Endometrial papillary carcinoma: Two clinical pathological types. Int J Gynecol Pathol 1985, 4:279.
158. Christopherson WN, Alberhasky RC, Connely PJ Carcinoma of the endometrium. I: A clinicopathological study of clear cell carcinoma and secretory carcinoma. Cancer 1982, 49:1511.
159. Christopherson WN, Alberhasky RC, Connely PJ Carcinoma of the endometrium. II: Papillary adenocarcinoma: A clinico-pathological study of 46 patients. Am J Clin Pathol 1982, 77:534.
160. Connely PJ, Alberhasky RC, Christopherson WN Carcinoma of the endometrium. III: Analysis of 865 cases of adenocarcinoma and adenocanthoma. Obstet Gynecol 1982, 59:569.
161. Eifel P, Hendrickson M, Ross J, et al. Simultaneous presentation of carcinoma involving the ovary and uterine corpus. Cancer 1982, 50:163.
162. Gitsch G, Friedlander ML, Wain GV, et al. Uterine papillary serous carcinoma. Cancer 1995, 75:2239.
163. Goff BA, Kato D, Schmidt RA, et al. Uterine papillary serous carcinoma: Patterns of metastatic spread. Gynecol Oncol 1994, 54:264.
164. Hendrickson MR, Longacre TA, Kempson RL Uterine papillary serous carcinoma revisited. Gynecol Oncol 1991, 54:261.
165. Hendrickson MR, Ross J, Eifel PJ, et al. Adenocarcinoma of the endometrium: Analysis of 256 cases of carcinoma limited to the uterine corpus. Gynecol Oncol 1982, 13:373.
166. Jeffrey JF, Krepart GV, Lotocki RJ Papillary serous adenocarcinomas of the endometrium. Obstet Gynecol 1986, 67:670.
167. Kaku T, Tsukamoto N, Hachisuga T, et al. Endometrial carcinoma associated with hyperplasia. Gynecol Oncol 1996, 60:22.
168. Klein Z, Markovitch O, Altaras M, et al. Advanced endometrial adenocarcinoma following endometrial ablation: A case report and review of the literature. Int J Gynecol Cancer 1997, 7:163.
169. Kurman RJ, Scully RE Clear cell carcinoma of the endometrium: Analysis of 21 cases. Cancer 1976, 37:872.
170. Ng ABP, Reagan JW Incidence and prognosis of endometrial carcinoma by histologic grade and extent. Obstet Gynecol 1970, 35:437.
171. Ng ABP, et al. Mixed adenosquamous carcinoma of the endometrium. Am J Clin Pathol 1973, 59:765.
172. Parkash V, Carcangiu ML Uterine papillary serous carcinoma after radiation therapy for carcinoma of the cervix. Cancer 1992, 69:496.
173. Photopulos GJ, et al. Clear cell carcinoma of the endometrium. Cancer 1979, 43:1448.
174. Salazar OM, et al. Adenosquamous carcinoma of the endometrium. Cancer 1977, 40:119.
175. Schwartz PE, et al. Routine use of hysterography in endometrium carcinoma and postmenopausal bleeding. Obstet Gynecol 1975, 45:378.
176. Schwartz Z, Ohel G, Birkenfeld A, et al. Second primary malignancy in endometrial carcinoma patients. Gynecol Oncol 1985, 22:40.
177. Sherman ME, Bur ME, Kurman RJ P53 in endometrial cancer and its putative precursor: Evidence for diverse pathways of tumorigenesis. Hum Pathol 1995, 26:1268.
178. Silverberg SG, Bolin MG, DeGiorgi LS Adenoacanthoma and mixed adenosquamous carcinoma of the endometrium. Cancer 1972, 30:1307.
179. Silverberg SG, DeGiorgi LS Clear cell carcinoma of the endometrium: Clinical-pathological and ultra-structural findings. Cancer 1973, 31:1127.
180. Sivridis E, Fox H, Buckley CH Endometrial carcinoma: Two or three entities?. Int J Gynecol Cancer 1998, 8:183.
181. Umpierre SA, Burke TW, Tornos C, et al. Immunocytochemical analysis of uterine papillary serous carcinomas for estrogen and progesterone receptors. Int J Gynecol Pathol 1994, 13:127.
182. Zaino RJ, Kurtman R, Herbald D, et al. The significance of squamous differentiation. Cancer 1991, 68:2293.
183. Zaino RJ, Unger ER, Whitney C. Synchronous carcinomas of the uterine corpus and ovary. Gynecol Oncol 1984, 19:329.
184. Aapro M, Bolis G, Chevallier B, et al. An EORTC-GCCG randomized phase II trial of doxorubicin versus dox-cisplatin in endometrial carcinoma. Proc Am Soc Clin Oncol 1994, 13:275.
185. Arneson A Clinical results and histological changes following irradiation treatment of cancer of the corpus uteri. AJR 1936, 36:461.
186. Ball HG, Blessing JA, Lentz SS, et al. A phase II trial of paclitaxel in patients with advanced or recurrent adenocarcinoma of the endometrium: A Gynecologic Oncology Group study. Gynecol Oncol 1996, 62:278.
187. Behbakht K, Jordan EL, Casey C, et al. Prognostic indicators of survival in advanced endometrial cancer. Gynecol Oncol 1994, 55:363.
188. Ben-Shachar I, Pavelka J, Cohn DE, et al. Surgical Staging for Patients Presenting With Grade 1 Endometrial Carcinoma. Obstet Gynecol 2005, 105:487.
189. Bond WH Early uterine body carcinoma: Is postoperative vaginal irradiation any value?. Clin Radiol 1985, 36:619.
190. Bruchner HW, Deppe G. Combination chemotherapy of advanced endometrial adenocarcinoma and Adriamycin, cyclophosphamide, 5-fluorouracil, and medroxyprogesterone acetate. Obstet Gynecol 1977, 50:105.
191. Burke TW Selective pelvic and para-aortic lymphadenectomy. Oper Tech Gynecol Surg 1996, 1:17.
192. Carcangiu ML, Chambers JT Uterine papillary serous carcinoma. Gynecol Oncol 1992, 47:298.
193. Chambers JT, Chambers SK, Kohorn EI, et al. Uterine papillary serous carcinoma treated with intraperitoneal cisplatin and intravenous doxorubicin and cyclophosphamide. Gynecol Oncol 1996, 60:438.
194. Chambers JT, Rutherford TJ, Baker L, et al. Serous carcinoma of the uterus treated with cisplatin, doxorubicin and etoposide. Int J Gynecol Cancer 1998, 8:193.
195. Chapman JA, DiSaia PJ, Osann K, et al. Estrogen replacement in surgical stage I and II endometrial cancer survivors. Am J Obstet Gynecol 1996, 175:1195.
196. Chen SS Operative treatment in stage I endometrial carcinoma with deep myometrial invasion and/or grade 3 tumor surgically limited to the corpus uteri: No recurrence with only primary surgery. Cancer 1989, 63:1843.
197. Chi DS, Welshinger M, Venkatraman ES, et al. The role of surgical cytoreduction in stage IV endometrial carcinoma. Gynecol Oncol 1997, 67:56.
198. Childers JM Laparoscopic lymph node sampling. Oper Tech Gynecol Surg 1996, 1:22.
199. Chung C, Stryker J, Nahhas W. The role of adjuvant radiotherapy for Stage I endometrial carcinoma. Int J Radiat Oncol Biol Phys 1981, 7:1429.
200. Cliby WA, Clarke-Pearson DL, Dodge R, et al. Acute morbidity and mortality associated with selective pelvic and para-aortic lymphadenectomy in the surgical staging of endometrial adenocarcinoma. J Gynecol Tech 1995, 1:19.
201. Cohen CJ, et al. Multidrug treatment of advanced and recurrent endometrial carcinoma: A Gynecologic Oncology Group study. Obstet Gynecol 1984, 63:719.
202. Cohen CJ, Deppe G, Bruchner HW Treatment of advanced adenocarcinoma of the endometrium with melphalan, 5-fluorouracil, and medroxyprogesterone acetate: A preliminary study. Obstet Gynecol 1977, 50:415.
203. Corn BW, Lanciano RM, Greven KM, et al. Impact of improved irradiation technique, age and lymph node sampling on the severe complication rate of surgically staged endometrial cancer patients: A multivariate analysis. J Clin Oncol 1994, 12:510.
204. Adjuvant medroxyprogesterone acetate in high risk endometrial cancer. Int J Gynecol Cancer 1998, 8:387. COSA-NZ-UK Endometrial Cancer Study Groups.
205. Pelvic lymphadenectomy in high-risk endometrial cancer. Int J Gynecol Cancer 1996, 6:102. COSA-NZ-UK Endometrial Cancer Study Groups.
206. Creutzberg CL, van Putten WLJ, Koper PCM, et al. Surgery and postoperative radiotherapy versus surgery alone for patients with stage-1 endometrial carcinoma: multicentre randomised trial. Lancet 2000, 355:1404.
207. de Waal JC, Lochmuller H. Preoperative radium insertion in the management of carcinoma of the endometrium. Geburtshilfe Frauenheilkd 1982, 42:394.
208. DePalo G, et al. Adjuvant treatment with medroxyprogesterone acetate in pathological stage I endometrial cancer with myometrial invasion. Endometrial Cancers, 5th Cancer Research Workshop, Grenoble 1985, 209. Karger, Basel. R. Volla, S. Racinet, A. Vrousos (Eds.).
209. Deppe G, Cohen CJ, Bruckner WH Treatment of advanced endometrial carcinoma with cis-dichlorodiamine platinum (II) after intensive prior therapy. Gynecol Oncol 1980, 10:51.
210. Dotters DJ Preoperative CA125 in endometrial cancer. Is it useful?. Am J Obstet Gynecol 2000, 182:1328.
211. Elliott P, Green D, Coates M, et al. The efficacy of postoperative vaginal irradiation in preventing vaginal recurrence in endometrial cancer. Int J Gynecol Cancer 1994, 4:84.
212. Fanning J, Firestein S. Prospective evaluation of the morbidity of complete lymphadenectomy in endometrial cancer. Int J Gynecol Cancer 1998, 8:270.
213. Fanning J, Piver MS Serial CA125 levels during chemotherapy for metastatic or recurrent endometrial cancer. Obstet Gynecol 1991, 77:278.
214. Fleming GF, Brunetto VL, Cella D, et al. Phase III Trial of Doxorubicin Plus Cisplatin With or Without Paclitaxel Plus Filgrastim in Advanced Endometrial Carcinoma: A Gynecologic Oncology Group Study. J Clin Oncol 2004, 22:2159.
215. Fleming GF, Filiaci VL, Bentley RC, et al. Phase III randomized trial of doxorubicin + cisplatin versus doxorubicin + 24-h paclitaxel + filgrastim in endometrial carcinoma: a Gynecologic Oncology Group study. Ann Oncol 2004, 15:1173.
216. Gabriele A, Lissoni A, Cromio G, et al. Cisplatin, doxorubicin and cyclophosphamide (PAC) followed by radiation therapy in high-risk endometrial carcinoma. Int J Gynecol Cancer 1998, 8:397.
217. Gallagher CJ, Oliver RTD, Oram DH, et al. A new treatment for endometrial cancer with gonadotropin releasing hormonal analogue. Br J Obstet Gynaecol 1991, 98:1037.
218. Hyeman J The so-called Stockholm method and the results of treatment of
219. Kadar N, Homesley HD, Malfetano JH Prognostic factors in surgical stage III and IV carcinoma of the endometrium. Obstet Gynecol 1994, 84:983.
220. Kadar N, Malfetano JH, Homesley HD Determinants of survival of surgically staged patients with endometrial carcinoma histologically confined to the uterus. Obstet Gynecol 1992, 80:655.
221. Kauppila A, et al. Treatment of advanced endometrial adenocarcinoma with combined cytotoxic therapy. Cancer 1980, 46:2162.
222. Kauppila A Progestin therapy of endometrial, breast, and ovarian carcinoma. Acta Obstet Gynecol Scand 1984, 63:441.
223. Kelly H Radium therapy and cancer of the uterus. Trans Am Gynecol Soc 1916, 41:532.
224. Kelly RN, Baker WH The effect of 17-alpha-hydroxyprogesterone caproate on metastatic endometrial cancer. Conference on Experimental Clinical Cancer Chemotherapy 1960, National Cancer Institute, Bethesda, MD, Monograph 9.
225. Keys HM, Roberts JA, Brunetto VL, et al. A phase III trial of surgery with or without adjunctive external pelvic radiation therapy in intermediate risk endometrial adenocarcinoma: a Gynecologic Oncology Group study. Gynecol Oncol 2004, 92:744.
226. Kilgore LC, Partridge EE, Alvarez RD, et al. Adenocarcinoma of the endometrium: Survival comparison of patients with and without pelvic node sampling. Gynecol Oncol 1995, 56:26.
227. Kimmig R, Strowitzki T, Muller-Hocker J, et al. Conservative treatment of endometrial cancer permitting subsequent triplet pregnancy. Gynecol Oncol 1995, 58:255.
228. Kistner RW The effects of progesteronal agents on hyperplasia and carcinoma in situ of the endometrium. Int J Gynaecol Obstet 1970, 8:561.
229. Kohorn EI Gestagens and endometrial carcinoma. Gynecol Oncol 1976, 4:398.
230. Larson DM, Broste SK, Krawisz BR Surgery without radiotherapy for primary treatment of endometrial cancer. Obstet Gynecol 1998, 91:355.
231. Larson DM, Johnson K, Olson FA Pelvic and para-aortic lymphadenectomy for surgical staging of endometrial cancer: Morbidity and mortality. Obstet Gynecol 1992, 79:998.
232. Leijon T, Rosenberg P, Boeryd B Total abdominal hysterectomy and bilateral salpingo-oophorectomy. A sufficient treatment for patients with low risk endometrial carcinoma. Int J Gynecol Oncol 1997, 7:376.
233. Lellé RJ, Morley GW, Peters WA The role of vaginal hysterectomy in the treatment of endometrial carcinoma. Int J Gynecol Cancer 1994, 4:342.
234. Lentz SS, Brady MF, Major FJ, et al. High-dose megestrol acetate in advanced or recurrent endometrial carcinoma: A Gynecologic Oncology Group study. J Clin Oncol 1996, 14:357.
235. Lentz SS Advanced and recurrent endometrial carcinoma: Hormonal therapy. Semin Oncol 1994, 21:100.
236. Lewis B, Stallworthy JA, Cowdell R. Adenocarcinoma of the body of the uterus. J Obstet Gynaecol Br Commonw 1970, 77:343.
237. Lewis GC, Slack NH, Mortel R, et al. Adjuvant progestogen therapy in primary definitive treatment of endometrial cancer. Gynecol Oncol 1974, 2:368.
238. Long JH, Langdon RM, Cha SS, et al. Phase II trial of methotrexate, vinblastine, doxorubicin and cisplatin in advanced/recurrent endometrial carcinomas. Gynecol Oncol 1995, 58:240.
239. Macdonald RR, Thorogood J, Mason MK A randomized trial of progestogens in the primary treatment of endometrial carcinoma. Br J Obstet Gynaecol 1988, 95:166.
240. Maggino T, Romagnolo C, Landoni F, et al. An analysis of approaches to the management of endometrial cancer in North America: A CTF Study. Gynecol Oncol 1998, 68:274.
241. Malkasian GD, et al. Progestogen treatment of recurrent endometrial carcinoma. Am J Obstet Gynecol 1971, 110:15.
242. Mangioni C, DePalo G, DelVecchio M. Surgical pathologic staging in apparent stage I endometrial cancer. Int J Gynecol Cancer 1993, 3:373.
243. Massi G, Savino L, Susini T. Vaginal hysterectomy versus abdominal hysterectomy for the treatment of stage I endometrial adenocarcinoma. Am J Obstet Gynecol 1996, 174:1320.
244. Mohan DS, Samuels MA, Selim MA, et al. Long-term outcomes of therapeutic pelvic lymphadenectomy for stage I endometrial adenocarcinoma. Gynecol Oncol 1998, 70:165.
245. Monson RR, MacMahon B, Austin JH Postoperative irradiation and carcinoma of the endometrium. Cancer 1973, 31:630.
246. Moore DH, Fowler WC, Walton LA, et al. Morbidity of lymph node sampling in cancers of the uterine corpus and cervix. Obstet Gynecol 1985, 65:251.
247. Moore TO, Phillips PH, Nerenstone SR, et al. Systemic treatment of advanced and recurrent endometrial carcinomas: Current status and future direction. J Clin Oncol 1991, 9:1071.
248. Morris M, Alvarez RD, Kinney WK, Wilson TO Treatment of recurrent adenocarcinoma of the endometrium with pelvic exenteration. Gynecol Oncol 1996, 60:288.
249. Morrow CP et al: A randomized study of Adriamycin adjuvant chemotherapy for patients with high risk stage I and II (occult) endometrial carcinoma. Presented by the International Gynecologic Cancer Society, Amsterdam, October 1987.
250. Morrow CP, DiSaia PJ, Townsend DE Current management of endometrial carcinoma. Obstet Gynecol 1973, 42:399.
251. Muss HB Chemotherapy of metastatic endometrial cancer. Semin Oncol 1994, 21:107.
252. Niloff JM, Klug TL, Schaetzl E, et al. Elevation of serum CA125 in carcinoma of fallopian tube, endometrium, and endocervix. Am J Obstet Gynecol 1984, 148:1057.
253. Onsrud M, Kolstad P, Normann T. Postoperative external pelvic irradiation in carcinoma of the corpus stage I: A controlled clinical trial. Gynecol Oncol 1976, 4:222.
254. Orr JW, Holloway RW, Orr PF, Halimon JL Surgical staging of uterine cancer: An analysis of perioperative morbidity. Gynecol Oncol 1991, 42:209.
255. Patterson E, et al. Management of stage I carcinoma of the uterus. Obstet Gynecol 1982, 59:755.
256. FIGO Annual Report, years 1996-98. Int J Gynecol Obstet 2003, 79-118.
257. Piver MS, et al. Melphalan, 5-FU and medroxyprogesterone acetate in metastatic endometrial carcinoma. Obstet Gynecol 1987, 67:261.
258. Podratz KC, Mariani A, Webb MJ Staging and therapeutic value of lymphadenectomy in endometrial cancer (Editorial). Gynecol Oncol 1998, 70:163.
259. Potish RA, Twiggs LB, Adcock LL, et al. Para-aortic lymph node radiotherapy in cancer of the uterine corpus. Obstet Gynecol 1985, 65:251.
260. Poulsen HK, Jacobsen M, Bertelsen K, et al. Adjuvant radiation therapy is not necessary in the management of endometrial carcinoma stage I, low risk cases. Int J Gynecol Cancer 1996, 6:38.
261. Randall ME, Reisinger S. Radiation therapy and combined chemo-irradiation in advanced and recurrent endometrial carcinoma. Semin Oncol 1994, 21:91.
262. Rose PG, Cha SD, Tak WK, et al. Radiation therapy for surgically proven para-aortic node metastasis in endometrial cancer. Int J Radiat Oncol Biol Phys 1992, 24:229.
263. Rutledge FN The role of radical hysterectomy in adenocarcinoma of the endometrium. Gynecol Oncol 1974, 2:331.
264. Selman AE, Fowler JM, Martinez-Monge R, Copeland LJ Doxorubicin and/or cisplatin based chemotherapy for the treatment of endometrial carcinoma with retroperitoneal lymph node metastases. Int J Gynecol Cancer 1998, 8:423.
265. Seski JC, et al. Adriamycin and cyclophosphamide chemotherapy for disseminated endometrial cancer. Obstet Gynecol 1981, 58:88.
266. Seski JC Cisplatin chemotherapy for disseminated endometrial cancer. Obstet Gynecol 1982, 59:225.
267. Straughn JM, Huh WK, Kelly J, et al. Conservative Management of Stage I Endometrial Carcinoma after Surgical Staging. Gynecol Oncol 2002, 84:194.
268. Straughn JM, Huh WK, Orr JW, et al. Stage IC adenocarcinoma of the endometrium: survival comparisons of surgically staged patients with and without adjuvant radiation therapy. Gynecol Oncol 2003, 89:295.
269. Thigpen JT, et al. Phase II trial of Adriamycin in treatment of advanced or recurrent endometrial carcinoma. Cancer Treat Rep 1979, 63:21.
270. Thigpen JT, Blessing JA, DiSaia PJ, et al. A randomized comparison of doxorubicin alone versus doxorubicin plus cyclophosphamide in the management of advanced or recurrent endometrial carcinoma: A Gynecologic Oncology Group study. J Clin Oncol 1994, 12:1408.
271. Thigpen JT, Blessing JA, Homesley HD, et al. Phase II trial of doxorubicin with and without cisplatin in advanced or recurrent endometrial carcinoma: A Gynecologic Oncology Group (GOG) study. Proc Am Soc Clin Oncol 1993, 12:261.
272. Thigpen JT Cis-platinum in the treatment of advanced or recurrent cervix and uterine cancer. Cisplatin: Current Status and New Developments 1980, Academic Press, New York. A.W. Prestayka, S.T. Crooke, S.K. Carter (Eds.).
273. Thigpen T et al: A randomized comparison of Adriamycin with or without Cytoxan in the treatment of advanced recurrent adenocarcinoma (Abstract), Vol 4. American Society of Gynecologic Oncologists, May 1985, p 115.
274. Thigpen T, et al. Treatment of advanced early recurrent endometrial cancer with medroxyprogesterone acetate (Abstract). Society of Gynecologic Oncologists February 1985.
275. Thigpen T, Blessing J, Homesley H, et al. Phase III trail of doxorubicin H-cisplatin in advanced or recurrent endometrial carcinoma. Proc Am Soc Clin Oncol 1993, 12:261.
276. Thigpen T, Blessing J, Homesley H, et al. Phase III trial of doxorubicin with and without cisplatin in advanced or recurrent endometrial carcinoma. Proc Am Soc Clin Oncol 1993, 12:26.
277. Trimble EL, Kosary C, Park RC Lymph node sampling and survival in endometrial cancer. Gynecol Oncol 1998, 71:340.
278. Trope C, et al. A phase II study of cisplatin for recurrent corpus cancer. Eur J Cancer 1980, 16:1025.
279. Underwood PB, et al. Carcinoma of the endometrium: Radiation followed immediately by operation. Am J Obstet Gynecol 1977, 128:86.
280. Watanabe M, Aoki Y, Kase H, et al. Low risk endometrial cancer: A study of pelvic lymph node metastasis. Int J Gynecol Cancer 2003, 13:38-41.
281. Wharam MD, Phillips TL, Bagshawe MA The role of radiation therapy in clinical stage I carcinoma of the endometrium. AJR Am J Roentgenol 1976, 1:1081.
282. Zanetta G, Gabrielle GL, Cappellini A, Manggioni C. Conservative management of endometrial carcinoma with prolonged preservation of the uterus in a young patient. Int J Gynecol Cancer 1997, 7:332.
283. Zanotti KM, Belinson JL, Kennedy AW, et al. The use of paclitaxel and platinum-based chemotherapy in uterine papillary serous carcinoma. Gynecol Oncol 1999, 74:272.